Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Clinical Trials Cardiovascular Strategy

Acesion Seeks Partner For First-In-Class AF Program Following Phase II Success

Shifts Focus To Earlier Program

  • News

Executive Summary

Having reached proof-of-concept for its first-in-class SK ion channel inhibitor for atrial fibrillation, the Danish firm is on the hunt for a licensee as it moves its attention to its preclinical program for sinus rhythm maintenance.

You may also be interested in...



Big Pharma’s Big Problems: Insights From Novo Holdings CEO

Novo Holdings CEO Kasim Kutay discusses today’s financing challenges and tomorrows big pharma pipeline problems in an exclusive interview. Despite turbulent times, he is positive about the future of health care.

Finance Watch: October Begins With A VC Mega-Round For Newly Named Iambic

Private Company Edition: Iambic, formerly known as Entos, closed a $100m series B venture capital round to advance its AI-discovered therapeutics. Also, Evozyne raised $81m and Acesion brought in €45m in series B rounds, while Mogrify added $10m to bring its series A to $46m.

Bloom Harnesses Gut-Brain Axis To Develop ‘Bugs As Drugs’ For Rare Neurological Disease

Table

View full table

Topics

Related Companies

Tags:
Clinical Trials Cardiovascular Strategy
Latest Headlines

China VBP, Localization And Other Strategies - How Far And Which Way?

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

With One Launch Under Way, SpringWorks Ramps Up For A Second

Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar

See All
UsernamePublicRestriction

Register

SC148048

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By